PMV Pharmaceuticals (NASDAQ:PMVP) Share Price Breaks Below 200 Day Moving Average – Time to Sell?

Posted by Brenda Bartman on Nov 6th, 2026

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Get Free Report) shares passed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $1.30 and traded as low as $1.20. PMV Pharmaceuticals shares last traded at $1.2750, with a volume of 475,606 shares changing hands.

Analysts Set New Price Targets

PMVP has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of PMV Pharmaceuticals in a research note on Friday, September 4th. Weiss Ratings upgraded shares of PMV Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 24th. Finally, Wall Street Zen raised shares of PMV Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $4.33.

Check Out Our Latest Research Report on PMVP

PMV Pharmaceuticals Stock Down 3.8%

The firm has a 50-day moving average price of $1.39 and a two-hundred day moving average price of $1.30. The firm has a market cap of $68.16 million, a PE ratio of -0.90 and a beta of 1.52.

PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.05. Research analysts forecast that PMV Pharmaceuticals, Inc. will post -1.20 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC acquired a new stake in PMV Pharmaceuticals during the 2nd quarter worth $41,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of PMV Pharmaceuticals during the second quarter worth $43,000. Susquehanna International Group LLP purchased a new stake in shares of PMV Pharmaceuticals during the second quarter worth $50,000. Cooper Haims Advisors LLC acquired a new stake in shares of PMV Pharmaceuticals in the second quarter valued at about $52,000. Finally, Rangeley Capital LLC raised its position in shares of PMV Pharmaceuticals by 46.9% in the first quarter. Rangeley Capital LLC now owns 66,846 shares of the company’s stock valued at $83,000 after buying an additional 21,346 shares during the last quarter. Hedge funds and other institutional investors own 90.20% of the company’s stock.

About PMV Pharmaceuticals

(Get Free Report)

PMV Pharmaceuticals, Inc is a clinical-stage precision oncology company focused on developing therapies that target cancer-causing mutations in the tumor suppressor protein p53. The company aims to discover and develop small-molecule medicines designed to restore the normal tumor-suppressing function of mutant p53 proteins.

PMV’s lead product candidate is rezatapopt, also known as PC14586, an investigational oral therapy designed to selectively target the p53 Y220C mutation. This mutation occurs in a range of solid tumors, and rezatapopt is being evaluated for its potential to reactivate the altered p53 protein and inhibit cancer-cell growth.

Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals is advancing rezatapopt through clinical development in patients with advanced solid tumors containing the p53 Y220C mutation.